Emergent BioSolutions (FRA:ER4) LT-Debt-to-Total-Asset : 0.48 (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Emergent BioSolutions's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.48.

Emergent BioSolutions's long-term debt to total assets ratio increased from Dec. 2023 (0.25) to Dec. 2024 (0.48). It may suggest that Emergent BioSolutions is progressively becoming more dependent on debt to grow their business.

Emergent BioSolutions LT-Debt-to-Total-Asset Historical Data

The historical data trend for Emergent BioSolutions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions LT-Debt-to-Total-Asset Chart

Emergent BioSolutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.29

0.27

0.14

0.25

0.48

Emergent BioSolutions Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.25	0.25	0.30	0.45	0.48

Emergent BioSolutions LT-Debt-to-Total-Asset Calculation

Emergent BioSolutions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	633.834	/	1327.164
	=	0.48

Emergent BioSolutions's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	633.834	/	1327.164
	=	0.48

Emergent BioSolutions (FRA:ER4) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Emergent BioSolutions LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (FRA:ER4) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

EBS:USA 0IGA:UK ER4:Germany

Address

300 Professional Drive, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Headlines

No Headlines